<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553488</url>
  </required_header>
  <id_info>
    <org_study_id>BDT-ADD-07-002</org_study_id>
    <secondary_id>EudraCT number 2007-003924-39</secondary_id>
    <nct_id>NCT00553488</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating</brief_title>
  <official_title>A Mono Center Open Labeled, Randomized Study Examining the Effects of Intra-Dermal vs Subcutaneous Application of Regular Insulin or Rapid Acting Insulin Analogue on Postprandial Glycemic Excursions in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the effect of intra-dermal (ID) administration of regular and of
      rapid-acting insulin, before eating, on blood glucose levels for several hours after a
      standard meal (a mixed, liquid meal). Insulin will also be given normally, subcutaneously,
      for control or comparison purposes. The hypothesis or expectation is that ID insulin will
      work more quickly and control blood glucose levels better than SC injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have shown that intra-dermal (ID) insulin administration results in a more
      rapid onset of action in comparison to subcutaneous (SC) administration as measured by
      glucose infusion rate (GIR) under glucose clamp conditions.The aim of this study is to
      investigate whether ID administration of regular human insulin or rapid-acting insulin
      analogue leads to reduced postprandial glycemic excursions in comparison to SC application
      under highly standardized experimental conditions. Effects on the occurrence of hypoglycemia
      will also be investigated, as well as pK and pD comparisons between different insulin
      formulations administered ID. This is a mono-center, open-label, randomized, 5-period
      crossover study in patients with type 1 diabetes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of the blood glucose (BG) profile after the meal, with and without baseline correction.</measure>
    <time_frame>90 mins</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal BG (BGmax)</measure>
    <time_frame>Approximately 4 hours per injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total BG-AUC0-4 h</measure>
    <time_frame>Approximately 4 hrs per injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal BG (BGmin, time to BGmin (tBGmin)</measure>
    <time_frame>Approximately 4 hrs per injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin pharmacokinetics</measure>
    <time_frame>Approximately 4 hrs per injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and seriousness of adverse events</measure>
    <time_frame>Approximately 4 hrs per injections</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, examination of insulin application</measure>
    <time_frame>Approximately 4 hrs per injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to BGmax (tBGmax)</measure>
    <time_frame>Approximately 4 hours per injection</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular insulin SC at -17 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular insulin ID at -17 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular insulin ID at -2 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin lispro given SC at -2 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin lispro given ID at -2 mins</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular insulin (Humulin)</intervention_name>
    <description>Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro (Humalog)</intervention_name>
    <description>Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes for 1-15 years, on multiple daily injections (MDI) or insulin pump
             (CSII) in stable control with HbA1c &lt;= 9.0%.

          -  Able to attend clinic for 5 different days

        Exclusion Criteria:

          -  BMI &gt; 32 kg/m2

          -  Evidence of gastroparesis or impaired renal function or lipodystrophy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Kapitza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut fur Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut fur Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>D-41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <last_update_submitted>August 21, 2008</last_update_submitted>
  <last_update_submitted_qc>August 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Laurence Hirsch, Vice-President, Global Medical Affairs, Diabetes Care</name_title>
    <organization>BD</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>insulin</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>intra-dermal</keyword>
  <keyword>blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

